The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Dupixent becomes the first-ever targeted therapy for patients with COPD, the first biologic for the disease, and the first new treatment approach in Europe in over a decade. It has been cleared ...

However, Dupixent trials specifically enrolled patients with elevated blood eosinophils (≥300 cells/μL) at baseline, known to be linked with higher COPD exacerbation rates. Tezspire’s trials ...

Verona Pharma plc's Ohtuvayre, approved for COPD, has driven ... and competition from Dupixent and other established drugs raise concerns. Verona's unique MoA offers expansion opportunities ...